Abstract
Coronavirus (CoV) has been associated with several infectious disease outbreak in humans in the past two decades, including Severe respiratory syndrome coronavirus [SARS-CoV] in 2002-2003 and Middle East respiratory coronavirus [MERS-CoV] in 2012. An unexpected and unexplained respiratory infection commenced at Wuhan city, China, during the end of 2019, which was named as novel coronavirus disease [2019-nCoV or COVID-19] by the World Health Organization (WHO). It is considered to be a zoonotic disease, as it has nearly similar amino acid homology to SARS-CoV. Reports have revealed an unexpected increase in number of cases worldwide (214 countries and territories along with 2 international conveyances), which intimidates the public with human to human escalation through respiratory droplets and contact routes. This pandemic was declared as a public health emergency of international concern. It follows an extremely heterogeneous course from mild Flu like symptoms [fever, cough, sore throat, dyspnoea, fatigue, headache and malaise] to severe acute respiratory distress syndrome. According to epidemiological data, old age and pre-existing medical co-morbidities are considered to be the risk factors for COVIOD-19. Currently, laboratory-based "Real time-reversed transcription Polymerase chain reaction" [rtRT-PCR] remains the molecular test of choice for the etiologic diagnosis. That apart, several hematological, biochemical markers along with various inflammatory cytokines (lymphopenia, serum level of C-reactive protein, D-dimer, ferritin, Interleukin-6, cardiac troponin I) may be used to assess disease severity. As of now, there have been approximately more than 36 million cases worldwide and more than one million succumbed to the illness (2.91% estimated mortality rate). Based on reports, India has become the second worst coronavirus hit country with a total number of cases reaching 68 lakhs. The dearth of selected medication (anti-CoV) and unusual transmission ability of 2019-nCoV continue to be responsible for this uninterrupted escalation. Woefully, specific vaccines are yet to come up. Treatment options like broad-spectrum antiviral Remdesivir, and oxygen therapy are being evaluated to control this unprecedented health crisis, although none of these drugs are FDA (Food and drug administration) approved. The path of this pandemic is very undetermined and unpredictable. In the present scenario, efficacious prevention needs swift action from the standpoint of public health strategies, which entails strict surveillance, rapid detection, and implementation of a containment plan to curb this outbreak. This review article highlights the updates on novel coronavirus 2019 and the uninterrupted apocalyptic progress concerning the present situation. It also highlights various perspectives of effective therapeutic strategies to restrain this viral outbreak.
Highlights
An unexpected outbreak of pneumonia emerged in the people of Wuhan, China's Hubei province, during the end of 2019, which was contemplated to be initiated via zoonotic transmission connected to the seafood market [1]
The etiology was attributed to be a novel coronavirus (2019-nCoV) by metagenomic sequencing of bronchoalveolar lavage fluid of patients. This was named as severe acute respiratory syndrome coronavirus (SARS-CoV-2) by the International Committee on Taxonomy of Virus [ICTV], due to its high homology to SARS-CoV, responsible for acute respiratory distress syndrome (ARDS) in 2002-2003 [2]
The novel coronavirus [2019-nCoV], responsible for the recent pandemic, is confirmed to be a member of beta coronavirus. It is named as SARS-CoV-2 due to its high homology to SARS-CoV, a beta coronavirus which causes acute respiratory distress syndrome, with high mortality during 2002-2003 [6]
Summary
An unexpected outbreak of pneumonia emerged in the people of Wuhan, China's Hubei province, during the end of 2019, which was contemplated to be initiated via zoonotic transmission connected to the seafood market [1]. Fluorescent analysis confirmed that 2019-nCoV, having amino acid homology to SARS-CoV, might be able to use same human ACE2 receptor [angiotensin converting enzyme-2], which is highly expressed in the apical side of lungs epithelial cells in the alveolar space, that explains human to human transmission by infected droplets within the incubation period [6]. Dysregulation of host cell immune response has been elaborately studied in adult severe COVID-19 patients with acute respiratory distress syndrome, which resembles SARS-CoV to a great extent [1]. IL-6 and IL-10 take a protagonist role as a chemoattractant, assist in the differentiation of Blymphocytes, and prompts acute phase protein synthesis They accelerate the progression of the systemic inflammatory response, as evident from a large number of inflammatory cells in the lungs in severe COVID-19 patients. The need for effective treatment is imperative to stop the outbreak and to reduce mortality
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have